BioXcel Therapeutics, Inc. Depreciation
BioXcel Therapeutics, Inc. (BTAI) reported Depreciation of $18.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- BioXcel Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $18.00K, a 76.00% decline year-over-year.
- BioXcel Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $58.00K, a 23.68% decline year-over-year.
- BioXcel Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $74.00K, a 3.90% decline year-over-year.
- BioXcel Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $75.00K, a 2.60% decline year-over-year.
- BioXcel Therapeutics, Inc. depreciation for fiscal 2025 was $300.00K, a 2.91% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. depreciation for fiscal 2024 was $309.00K, a 2.83% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. depreciation for fiscal 2023 was $318.00K, a 2.75% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. depreciation for fiscal 2022 was $327.00K, a 10.10% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.00K 10-Q · filed 2026-08-13 | $76.00K 10-Q · filed 2026-08-13 | $150.00K derived: sum of 3 quarters · filed 2026-08-13 | $225.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $58.00K 10-Q · filed 2026-05-15 | $132.00K derived: sum of 2 quarters · filed 2026-05-15 | $207.00K derived: sum of 3 quarters · filed 2026-05-15 | $282.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $149.00K derived: sum of 2 quarters · filed 2026-03-27 | $224.00K derived: sum of 3 quarters · filed 2026-08-13 | $300.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $75.00K 10-Q · filed 2025-11-12 | $150.00K derived: sum of 2 quarters · filed 2026-08-13 | $226.00K 10-Q · filed 2025-11-12 | $303.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $75.00K 10-Q · filed 2026-08-13 | $151.00K 10-Q · filed 2026-08-13 | $228.00K derived: sum of 3 quarters · filed 2026-08-13 | $305.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $76.00K 10-Q · filed 2026-05-15 | $153.00K derived: sum of 2 quarters · filed 2026-05-15 | $230.00K derived: sum of 3 quarters · filed 2026-05-15 | $307.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $154.00K derived: sum of 2 quarters · filed 2026-03-27 | $231.00K derived: sum of 3 quarters · filed 2026-03-27 | $309.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $77.00K 10-Q · filed 2025-11-12 | $154.00K derived: sum of 2 quarters · filed 2025-11-12 | $232.00K 10-Q · filed 2025-11-12 | $310.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $77.00K 10-Q · filed 2025-08-12 | $155.00K 10-Q · filed 2025-08-12 | $233.00K derived: sum of 3 quarters · filed 2025-08-12 | $312.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $78.00K 10-Q · filed 2025-05-12 | $156.00K derived: sum of 2 quarters · filed 2025-05-12 | $235.00K derived: sum of 3 quarters · filed 2025-05-12 | $316.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $157.00K derived: sum of 2 quarters · filed 2025-03-28 | $238.00K derived: sum of 3 quarters · filed 2025-03-28 | $318.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $79.00K 10-Q · filed 2024-11-14 | $160.00K derived: sum of 2 quarters · filed 2024-11-14 | $240.00K 10-Q · filed 2024-11-14 | $321.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $81.00K 10-Q · filed 2024-08-06 | $161.00K 10-Q · filed 2024-08-06 | $242.00K derived: sum of 3 quarters · filed 2024-08-06 | $327.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $80.00K 10-Q · filed 2024-05-09 | $161.00K derived: sum of 2 quarters · filed 2024-05-09 | $246.00K derived: sum of 3 quarters · filed 2024-05-09 | $330.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $166.00K derived: sum of 2 quarters · filed 2024-03-22 | $250.00K derived: sum of 3 quarters · filed 2024-03-22 | $327.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | $85.00K 10-Q · filed 2023-11-14 | $169.00K derived: sum of 2 quarters · filed 2023-11-14 | $246.00K 10-Q · filed 2023-11-14 | $322.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $84.00K 10-Q · filed 2023-08-14 | $161.00K 10-Q · filed 2023-08-14 | $237.00K derived: sum of 3 quarters · filed 2023-08-14 | $313.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $77.00K 10-Q · filed 2023-05-09 | $153.00K derived: sum of 2 quarters · filed 2023-05-09 | $229.00K derived: sum of 3 quarters · filed 2023-05-09 | $309.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $152.00K derived: sum of 2 quarters · filed 2023-03-16 | $232.00K derived: sum of 3 quarters · filed 2023-03-16 | $297.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $76.00K 10-Q · filed 2022-11-14 | $156.00K derived: sum of 2 quarters · filed 2022-11-14 | $221.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $80.00K 10-Q · filed 2022-08-11 | $144.00K 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | $188.00K 10-K · filed 2021-03-12 | |||
| 2019-12-31 | $155.00K 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |